TALAGAS
Brest, 29200, France
NCT Number: NCT04848194
Widely expressed in the sensory nerve endings of the skin, Transient Receptor Potential Vanilloid 1 (TRPV1) is a receptor that plays an important role in the perception of pain and pruritus but also in skin inflammation, primarily by inducing the local release of several neuropeptides.
Although the mechanisms by which TRPV1-sensitizing inflammatory mediators in damaged skin have received considerable attention, the role of TRPV1 in psoriasis has so far been little explored.
However, two studies have reported that ablation of sensory nerves expressing TRPV1 reduced psoriasiform skin inflammation, demonstrating the neuronal contribution to inflammation in psoriasis.
However, the expression of TRPV1 is not limited to neurons alone. TRPV1 is also expressed by epidermal keratinocytes and skin microvessels.
For example, in 2018, transcriptomic analysis of psoriatic patient skins (by definition devoid of neuron nuclei) revealed that TRPV1 expression was increased in the skin of psoriatic patients suffering from itching (pruritus).
Regarding human keratinocytes, it is recognized that the activation of TRPV1 present on their surface induces the release of pro-inflammatory factors such as cyclooxygenase-2. In addition, the investigators have demonstrated that TRPV1 has a pivotal role in the keratinocyte production of inflammatory mediators, which is mediated by the protease-activated receptor-2 (PAR-2). However, the role of vascular TRPV1 in inflammation is not described.
The investigators hypothesize that in addition to neuronal TRPV1, non-neuronal TRPV1 receptors of non-neuronal cells (keratinocytes and endothelial cells) may be involved in the vicious circle of the inflammatory process characteristic of psoriasis. Putting TRPV1 at the center of the deregulation of the homeostatic balance including epithelial, neuronal and vascular inflammation in psoriasis is totally innovative.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Brest, 29200, France
Each patient will have a sample taken in the dermatology department:
Patients with psoriasis will be recruited from the dermatology department. There will be no further visits, so the duration of the study is 1 day.
The samples taken will be used to determine the pleiotropic role of TRPV1 in Psoriasis Inflammation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 day
Density of intra-epidermal nerve fibers expressing the TRPV1 receptor
Time frame: 1 day
Density of intra-epidermal nerve fibers expressing neuropeptides by immunohistochemistry
Time frame: 1 day
quantification of the transcriptional and protein expression of TRPV1
Time frame: 1 day
quantification of TRPV1 activity
Time frame: 1 day
Identification and quantification of the blood cytokine profile
Time frame: 1 day
Number and distribution of contacts between keratinocytes and nerve fibers
University Hospital, Brest
Other
Acronym: TRIP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05110313
Aging, Dermatitis
Providence, Rhode Island, United States
View Trial DetailsNCT03183830
Cardiovascular Diseases, Dermatitis
London, United Kingdom
View Trial DetailsNCT04308889
Blister, Dermatitis
Boston, Massachusetts, United States
View Trial DetailsNCT03779360
Dermatitis, Inflammation; Skin
Leiden, South Holland, Netherlands
View Trial Details